Federated Investors Inc. PA Purchases 44 Shares of Amedisys Inc (AMED)
Federated Investors Inc. PA raised its position in Amedisys Inc (NASDAQ:AMED) by 2.3% in the second quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 1,929 shares of the health services provider’s stock after acquiring an additional 44 shares during the quarter. Federated Investors Inc. PA’s holdings in Amedisys were worth $122,000 as of its most recent SEC filing.
A number of other institutional investors have also recently modified their holdings of AMED. BlackRock Inc. raised its holdings in Amedisys by 2,877.7% during the first quarter. BlackRock Inc. now owns 5,676,870 shares of the health services provider’s stock worth $290,032,000 after purchasing an additional 5,486,225 shares in the last quarter. Bank of New York Mellon Corp raised its holdings in Amedisys by 125.0% during the first quarter. Bank of New York Mellon Corp now owns 781,256 shares of the health services provider’s stock worth $39,915,000 after purchasing an additional 433,956 shares in the last quarter. Russell Investments Group Ltd. raised its holdings in Amedisys by 662.7% during the second quarter. Russell Investments Group Ltd. now owns 276,808 shares of the health services provider’s stock worth $17,387,000 after purchasing an additional 240,513 shares in the last quarter. FMR LLC raised its holdings in Amedisys by 6.9% during the first quarter. FMR LLC now owns 2,352,632 shares of the health services provider’s stock worth $120,196,000 after purchasing an additional 152,632 shares in the last quarter. Finally, Victory Capital Management Inc. raised its holdings in Amedisys by 26.3% during the first quarter. Victory Capital Management Inc. now owns 692,159 shares of the health services provider’s stock worth $35,362,000 after purchasing an additional 144,044 shares in the last quarter. Institutional investors own 96.55% of the company’s stock.
Shares of Amedisys Inc (NASDAQ:AMED) opened at 52.80 on Tuesday. The stock has a market capitalization of $1.79 billion, a price-to-earnings ratio of 45.13 and a beta of 0.84. Amedisys Inc has a 12 month low of $34.58 and a 12 month high of $65.91. The firm’s 50 day moving average is $50.25 and its 200 day moving average is $54.94.
Amedisys (NASDAQ:AMED) last issued its quarterly earnings results on Wednesday, July 26th. The health services provider reported $0.62 EPS for the quarter, beating analysts’ consensus estimates of $0.50 by $0.12. The company had revenue of $378.80 million for the quarter, compared to analyst estimates of $380.80 million. Amedisys had a return on equity of 13.71% and a net margin of 2.70%. The company’s quarterly revenue was up 5.0% compared to the same quarter last year. During the same period last year, the company earned $0.42 earnings per share. On average, equities analysts predict that Amedisys Inc will post $2.21 earnings per share for the current fiscal year.
AMED has been the topic of a number of research analyst reports. Oppenheimer Holdings, Inc. reissued a “buy” rating and set a $60.00 price objective on shares of Amedisys in a report on Friday, September 15th. BidaskClub cut shares of Amedisys from a “strong-buy” rating to a “buy” rating in a report on Wednesday, July 12th. Royal Bank Of Canada reissued a “hold” rating and set a $56.00 price objective on shares of Amedisys in a report on Monday, June 5th. Mizuho cut shares of Amedisys from a “buy” rating to a “neutral” rating and set a $50.00 target price on the stock. in a report on Wednesday, July 26th. Finally, Bank of America Corporation began coverage on shares of Amedisys in a report on Monday, August 21st. They issued a “neutral” rating and a $55.00 target price on the stock. Seven investment analysts have rated the stock with a hold rating and three have given a buy rating to the company’s stock. The stock has a consensus rating of “Hold” and an average price target of $56.44.
TRADEMARK VIOLATION NOTICE: This report was first posted by Daily Political and is owned by of Daily Political. If you are reading this report on another site, it was stolen and republished in violation of US & international trademark & copyright law. The original version of this report can be accessed at https://www.dailypolitical.com/2017/09/26/federated-investors-inc-pa-purchases-44-shares-of-amedisys-inc-amed.html.
In other news, Director Bruce D. Perkins bought 2,000 shares of the firm’s stock in a transaction that occurred on Thursday, August 3rd. The stock was acquired at an average price of $46.60 per share, with a total value of $93,200.00. Following the completion of the purchase, the director now directly owns 15,825 shares of the company’s stock, valued at approximately $737,445. The acquisition was disclosed in a filing with the SEC, which is available at this link. Also, insider David B. Pearce sold 1,000 shares of the firm’s stock in a transaction dated Tuesday, August 8th. The shares were sold at an average price of $50.00, for a total value of $50,000.00. Following the transaction, the insider now directly owns 10,488 shares of the company’s stock, valued at approximately $524,400. The disclosure for this sale can be found here. 2.80% of the stock is currently owned by company insiders.
Amedisys Company Profile
Amedisys, Inc is a healthcare services company. The Company’s segments are Home Health, Hospice, Personal Care and Other. The Company is a provider of home health, hospice and personal care services. As of December 31, 2016, the Company owned and operated 327 Medicare-certified home healthcare centers, 79 Medicare-certified hospice care centers and 14 personal-care care centers in 34 states within the United States and the District of Columbia.
Want to see what other hedge funds are holding AMED? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Amedisys Inc (NASDAQ:AMED).
Receive News & Ratings for Amedisys Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Amedisys Inc and related companies with MarketBeat.com's FREE daily email newsletter.